about
Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMPSLC transporters as therapeutic targets: emerging opportunitiesGenetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variationGenomic Characterization of Metformin Hepatic ResponseMembrane transporters in drug developmentComputational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotypeVariants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8)Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.Functional characterization of liver enhancers that regulate drug-associated transporters.Pharmacogenomics of membrane transporters: past, present and futureOrganic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metforminGenome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping.Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell linesGenomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine.Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells.Prediction and validation of enzyme and transporter off-targets for metformin.Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles.Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.SLC classification: an updateSynthesis and CYP24A1 inhibitory activity of N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides.OCT1 in hepatic steatosis and thiamine disposition.The role of ATM in response to metformin treatment and activation of AMPK.International Transporter Consortium commentary on clinically important transporter polymorphisms.Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation.
P50
Q24644047-DFF40BEB-F346-4A78-8C90-A2F7846299B1Q27014726-67570E0F-CBD7-4E67-9C50-F74C120DE442Q28476093-C3C6AD35-5652-425D-BA62-E04D8BAF79F6Q28554592-3B232B82-5AEC-40B3-93BA-AEF84A711AE3Q29616802-757F33A6-361F-40F8-B056-CAE7B8E8AF2AQ30402582-8F161038-2839-4E30-8D5A-0C14E535C4E1Q33633486-6091E729-5C19-4B66-921A-6AC5A667700CQ33658321-1694FE3F-C8B4-4F09-A4F4-ADCB07C1FB9DQ33919545-CEB2894D-7A86-4ED7-A110-8E96488354EBQ34071782-09602FFC-38BF-4C49-84EC-F2FD5BD780B8Q34117674-96AFA7CB-12C8-4FA0-8277-CE194A98BA91Q34224429-7988D658-A99B-486B-AC43-968FC085020AQ35014972-FEBEDC65-DCDD-4AE1-BB32-332B74235057Q35583006-EA62A4EE-A8B3-45BA-BBFE-DAE3B7EA260CQ35603055-E472F59F-15A6-49EB-A5E4-214829FCE3E8Q35671906-0A410574-AB38-43A2-8FD9-E92F37D2E4D0Q35745939-6702BC2B-00C7-439A-A125-8E6E9E74E2F3Q35775875-C6D72C32-1B58-4613-9A33-D87937681F90Q35886142-909F7889-A8E6-45E2-8165-3562E148EAA9Q36288247-16775CAD-50AF-453C-A731-1EE3DFDCED8EQ36709745-F3E88831-A805-468C-9CFB-7019A2F52EF3Q36899802-32DDA15C-7427-4612-807F-023B9FBC0845Q36924379-9F52E00D-50EE-4A65-90D2-EE4855B19159Q36999783-F21A225B-0272-402B-A608-C0B4AD504BB5Q37165815-B7668110-0BD1-4674-A0C7-D92647437920Q37323259-7B74B158-6918-4792-94E1-EAFDA060323FQ38631094-3FE165FD-67AC-4747-AFCB-2C471E1BEF71Q38809316-DA7EBB69-FADD-4185-B108-61E5D2E11C67Q38838317-0D84AFB2-B2EB-40C4-B037-602E3A23B167Q38838835-F774EE73-8BF7-4C2E-B11E-01F5DE42D593Q39602527-9FE2BE99-7874-4514-AA37-AF3B001F92C5Q39778798-CCDA7F70-2AE6-4F03-BA25-85F03B396C0DQ40320595-D58985F7-42A4-4E80-AA6A-CB18A8CDEFF5Q40352814-A090B646-D71E-4E33-AEA1-50E66F8DFA7EQ42082729-BE87B716-A334-4CA5-8DFE-4FF6E341967BQ42994944-61D0C103-94CC-4469-96F1-807F33FBCE5EQ43180142-389EA7DB-4258-43AA-8126-8597AF39647EQ43181508-C6D44F1D-F623-4BE1-A8AF-C09718FCFA18Q45082643-2E2B42EF-F01C-4985-AB7B-86896C23A9BEQ46922543-CAC24C29-978F-4CA3-B65C-26ACFE61A164
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Sook Wah Yee
@en
Sook Wah Yee
@nl
type
label
Sook Wah Yee
@en
Sook Wah Yee
@nl
prefLabel
Sook Wah Yee
@en
Sook Wah Yee
@nl
P31
P496
0000-0001-8121-8746